We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Molecular Test Identifies Brain Tumors from Cerebrospinal Fluid

By LabMedica International staff writers
Posted on 07 Sep 2023

Doctors generally use MRI scans and biopsies to check for brain tumors. But sometimes, it's hard to tell if a brain lesion is cancerous or not using these usual methods. Now, researchers have developed a molecular test to identify the presence of brain tumors by measuring unusual genetic material that is released by tumors and circulates in cerebrospinal fluid (CSF).

Researchers at Johns Hopkins Medicine (Baltimore, MD, USA) have developed Real-CSF (repetitive element aneuploidy sequencing in CSF), a novel test that assesses aneuploidy (chromosome copy number alterations found in cancers) in over 350,000 regions of the genome simultaneously. Using a companion bioinformatics algorithm and machine-learning process, the test can identify the presence of cancers and their molecular characteristics in just two milliliters of CSF.

When the researchers tested Real-CSF in the lab using 280 CSF samples from people, some with brain cancer and some without, it accurately identified 67% of the cancerous brain lesions and 96% of the noncancerous ones. This outperformed the usual cytology testing approach, which only found 23% of cancers in a group of 121 patients. If more studies and tests show that Real-CSF works well, it could help doctors decide if a brain lesion is cancerous or not. It could also help them see how brain tumors are responding to treatment. The researchers now aim to make the test even better by combining it with gene mutations linked to cancer or changes in DNA that are only found in cancer.

“The test is very simple to use, works even on a limited amount of CSF and is inexpensive relative to many of the other liquid biopsy approaches on the market,” said senior study author Chetan Bettegowda, M.D., Ph.D. “With those characteristics, we were quite pleased that we had such a robust performance.”

Related Links:
Johns Hopkins Medicine 

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centrifuge
Hematocrit Centrifuge 7511M4
New
Coagulation Analyzer
CS-2400
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.